New advances in the management of acute coronary syndromes: 2. Fibrinolytic therapy for acute ST-segment elevation myocardial infarction.
作者信息
Armstrong P W
机构信息
University of Alberta, Edmonton, Alta.
出版信息
CMAJ. 2001 Sep 18;165(6):791-7.
Abstract
摘要
相似文献
1
2
Fibrinolytic therapy for acute ST-segment elevation myocardial infarction.急性ST段抬高型心肌梗死的纤维蛋白溶解疗法。
CMAJ. 2002 Mar 19;166(6):708; author reply 708, 710.
3
4
Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes.急性冠状动脉综合征的溶栓、抗凝血酶和抗血小板治疗。
J Am Osteopath Assoc. 2000 Nov;100(11 Suppl):S8-12.
5
Thrombolytics and myocardial infarction.溶栓治疗与心肌梗死。
Cardiovasc Ther. 2012 Apr;30(2):e81-8. doi: 10.1111/j.1755-5922.2010.00239.x. Epub 2010 Nov 11.
6
Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
Can J Cardiol. 1993 Jul-Aug;9(6):553-8.
7
[Thrombolysis (Consensus about post-myocardial infarction treatment)].
Arq Bras Cardiol. 1995 Mar;64(3):271-80.
8
[Thrombolysis in myocardial infarct: findings and prospects].[心肌梗死的溶栓治疗：研究结果与前景]
Ann Ital Med Int. 1987 Jul-Sep;2(3):241-8.
9
[Plasminogen activators as thrombolytic agents in myocardial infarction].[纤溶酶原激活剂作为心肌梗死的溶栓药物]
Rev Hosp Clin Fac Med Sao Paulo. 1989 Nov-Dec;44(6):288-94.
10
[Fibrinolytic therapy].
Hamostaseologie. 2008 Dec;28(5):428-37.
引用本文的文献
1
Quality of care of patients with acute myocardial infarction in Bulgaria: a cross-sectional study.保加利亚急性心肌梗死患者的医疗质量：一项横断面研究。
BMC Health Serv Res. 2009 Jan 26;9:15. doi: 10.1186/1472-6963-9-15.
2
3
Rising to the challenge: transforming the treatment of ST-segment elevation myocardial infarction.迎接挑战：变革ST段抬高型心肌梗死的治疗方法
CMAJ. 2003 Jul 8;169(1):35-7.
4
5
Fibrinolytic therapy for acute ST-segment elevation myocardial infarction.急性ST段抬高型心肌梗死的纤维蛋白溶解疗法。
CMAJ. 2002 Mar 19;166(6):708; author reply 708, 710.
本文引用的文献
1
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.替奈普酶与依诺肝素、阿昔单抗或普通肝素联合使用的疗效和安全性：急性心肌梗死的ASSENT-3随机试验
Lancet. 2001 Aug 25;358(9282):605-13. doi: 10.1016/S0140-6736(01)05775-0.
2
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.急性心肌梗死的再灌注治疗：采用纤溶疗法或联合降低纤溶疗法及血小板糖蛋白IIb/IIIa抑制作用的治疗——GUSTO V随机试验
Lancet. 2001 Jun 16;357(9272):1905-14. doi: 10.1016/s0140-6736(00)05059-5.
3
Bolus fibrinolysis: risk, benefit, and opportunities.大剂量纤维蛋白溶解疗法：风险、益处与机遇
Circulation. 2001 Feb 27;103(8):1171-3. doi: 10.1161/01.cir.103.8.1171.
4
Thrombolytic therapy in the elderly.
Lancet. 2000 Dec 16;356(9247):2028-30. doi: 10.1016/S0140-6736(00)03397-3.
5
Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis.推注与输注溶栓治疗颅内出血的风险：一项荟萃分析。
Lancet. 2000 Aug 5;356(9228):449-54. doi: 10.1016/S0140-6736(00)02552-6.
6
Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators.急性心肌梗死中冠状动脉支架置入术联合血小板糖蛋白IIb/IIIa阻滞剂与组织型纤溶酶原激活剂的比较。急性心肌梗死患者闭塞冠状动脉支架与溶栓治疗研究组。
N Engl J Med. 2000 Aug 10;343(6):385-91. doi: 10.1056/NEJM200008103430602.
7
8
Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.阿昔单抗联合或不联合低剂量瑞替普酶治疗急性心肌梗死的试验。急诊科血管开通强化策略（SPEED）研究组。
Circulation. 2000 Jun 20;101(24):2788-94. doi: 10.1161/01.cir.101.24.2788.
9
Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years.
Circulation. 2000 May 16;101(19):2239-46. doi: 10.1161/01.cir.101.19.2239.
10
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.急性心肌梗死中单次推注替奈普酶与先负荷剂量阿替普酶的比较：ASSENT-2双盲随机试验
Lancet. 1999 Aug 28;354(9180):716-22. doi: 10.1016/s0140-6736(99)07403-6.
Zotero 插件